<DOC>
	<DOCNO>NCT01380119</DOCNO>
	<brief_summary>This phase II , randomize , placebo-controlled trial , aim seek therapeutic benefit V7 combination standard care anti-Tuberculosis ( TB ) therapy ( ATT ) among Mycobacterium tuberculosis-infected sputum smear positive subject . The result compare placebo combine standard ATT therapy . The trial consist one stage sputum evaluation month 1 2 .</brief_summary>
	<brief_title>Tuberculosis ( TB ) Immunotherapy Phase 2 Study</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>Subjects least 18 year old willing capable providing inform consent . Both men nonpregnant woman include . TB infection document prior Study Entry sputum smear positive acidfast bacillus ( AFB ) test . TB score status baseline . Agreement participate study give sample blood lab test . Readily available home address patient find . Subjects might already take V5 prior trial baseline data . Pregnant breastfeed woman exclude . Subjects take study unrelated drug immunomodulatory therapy study prior Entry . Medical condition active alcohol substance abuse , psychological issue opinion local investigator would interfere adherence requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>sputum conversion</keyword>
	<keyword>liver biochemistry</keyword>
	<keyword>weight loss</keyword>
	<keyword>quality life</keyword>
</DOC>